Hemophilia A Therapeutics Development Pipeline Overview for H1 2017

ReportsnReports.com adds Hemophilia A – Pipeline Review, H1 2017 a new research reports in its store.  Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage.

Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010769

Hemophilia A – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Companies of the Hemophilia A Pipeline Market are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Apitope International NV , Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd , CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, Emergent BioSolutions Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, Lentigen Technology Inc, mAbxience SA, Novo Nordisk A/S, OPKO Biologics Ltd, Pangen Biotech Inc., Pfizer Inc, Pharming Group NV, Promethera Biosciences SA, rEVO Biologics Inc, Sangamo Therapeutics Inc, Shire Plc, SK Chemicals Co Ltd, Spark Therapeutics Inc, UniQure NV, XL-protein GmbH

Hemophilia A – Drug Profiles : ATXF-8117, BAX-888, BAY-1093884, BIVV-001, BMN-270, Cell Therapy to Target Coagulation Factor VIII for Hemophilia A, coagulation factor VIIa (recombinant), concizumab, CSL-689, damoctocog alfa pegol, Deimmunized FVIII, DTX-201, emicizumab, ET-3, fitusiran, Gene Therapy for Hematological Disorders, Gene Therapy for Hemophilia A, Gene Therapy to Activate Factor VIII for Hemophilia A, HepaStem, IN-3012, Kovaltry more..

Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1010769 (This report is available at upto 25% Discount till June 02^nd 2017.)

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010769

List of Figures
Number of Products under Development for Hemophilia A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

About Us:          

ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help in purchase decision by mapping your information needs with our huge collection of reports.